Dermatology revenue depends on counting and separation logic. Premalignant lesion destruction is billed once for the first lesion (17000) and per-lesion for the next thirteen (17003), then flattens to a single flat-rate code at fifteen or more (17004). Biopsies and excisions on the same patient trip NCCI bundling unless the distinct-service rationale is documented and coded with modifier 59 or the appropriate X-modifier.
Lesion destruction arithmetic is the fastest place revenue silently disappears. A clinician who destroys eleven actinic keratoses must be billed as one 17000 plus ten units of 17003 — not as a single code. In the other direction, billing individual lesions past fifteen when the flat 17004 rate applies overstates the claim and invites recoupment. Correct codes come from counting and documenting lesions in the note, not from procedure labels on the schedule.
Same-day distinct procedures are the second pressure point. When a patient has a biopsy (11102–11107) and a lesion destruction in one visit, payers apply NCCI Procedure-to-Procedure edits unless the services are genuinely distinct — documented by site, lesion and intent, and reported with modifier 59 or the XS family. Cloned but unmodified claims deny; over-modification triggers audits. The line between the two is purely documentational.
Mohs is a discipline of its own. Each stage is billed with the first-stage codes (17311–17313 by site and histology) followed by add-on codes (17314–17315) as additional stages and blocks are performed, and the pathology interpretation itself follows separate rules. Because Mohs revenue per patient is high, sequencing errors are correspondingly expensive. Our dermatology desk tracks stage counts, block counts and same-day pathology to keep every Mohs claim defensible.
“48% of leaders named denials and appeals their practice’s largest source of revenue leakage, compared with 23% who cited front-end issues.”